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Abstract. We introduce Disease Knowledge Transfer (DKT), a novel
technique for transferring biomarker information between related neu-
rodegenerative diseases. DKT infers robust multimodal biomarker tra-
jectories in rare neurodegenerative diseases even when only limited, uni-
modal data is available, by transferring information from larger mul-
timodal datasets from common neurodegenerative diseases. DKT is a
joint-disease generative model of biomarker progressions, which exploits
biomarker relationships that are shared across diseases. Our proposed
method allows, for the first time, the estimation of plausible multimodal
biomarker trajectories in Posterior Cortical Atrophy (PCA), a rare neu-
rodegenerative disease where only unimodal MRI data is available. For
this we train DKT on a combined dataset containing subjects with two
distinct diseases and sizes of data available: 1) a larger, multimodal typ-
ical AD (tAD) dataset from the TADPOLE Challenge, and 2) a smaller
unimodal Posterior Cortical Atrophy (PCA) dataset from the Dementia
Research Centre (DRC), for which only a limited number of Magnetic
Resonance Imaging (MRI) scans are available. Although validation is
challenging due to lack of data in PCA, we validate DKT on synthetic
data and two patient datasets (TADPOLE and PCA cohorts), show-
ing it can estimate the ground truth parameters in the simulation and
predict unseen biomarkers on the two patient datasets. While we demon-
strated DKT on Alzheimer’s variants, we note DKT is generalisable to
other forms of related neurodegenerative diseases. Source code for DKT
is available online: https://github.com/mrazvan22/dkt.
Keywords: Disease Progression Modelling, Transfer Learning, Mani-
fold Learning, Alzheimer’s Disease, Posterior Cortical Atrophy
1 Introduction
The estimation of accurate biomarker signatures in Alzheimer’s disease (AD)
and related neurodegenerative diseases is crucial for understanding underlying
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disease mechanisms, predicting subjects’ progressions, and enrichment in clin-
ical trials. Recently, data-driven disease progression models were proposed to
reconstruct long term biomarker signatures from collections of short term indi-
vidual measurements [1,2]. When applied to large datasets of typical AD, disease
progression models have shown important benefits in understanding the earli-
est events in the AD cascade [1], quantifying biomarkers’ heterogeneity [3] and
they showed improved predictions over standard approaches [1]. However, by
necessity these models require large datasets – in addition they should be both
multimodal and longitudinal. Such data is not always available in rare neurode-
generative diseases. In particular, most datasets for rare neurodegenerative dis-
eases come from local clinical centres, are unimodal (e.g. MRI only) and limited
both cross-sectionally and longitudinally – this makes the application of disease
progression models extremely difficult. Moreover, such a model estimated from
common diseases such as typical AD may not generalise to specific variants.
For example, in Posterior Cortical Atrophy (PCA) – a neurodegenerative syn-
drome causing visual disruption – posterior regions such as the occipital lobe are
affected early, instead of the hippocampus and temporal regions in typical AD.
The problem of limited data in medical imaging has so far been addressed
through transfer learning methods. These were successfully used to improve the
accuracy of AD diagnosis [4] or prediction of MCI conversion [5], but have two
key limitations. First, they use deep learning or other machine learning methods,
which are not easily interpretable and don’t allow us to understand underlying
disease mechanisms that are either specific to rare diseases, or shared across
related diseases. Secondly, these models cannot be used to forecast the future
evolution of subjects at risk of disease, which is important for selecting the right
subjects in clinical trials.
We propose Disease Knowledge Transfer (DKT), a generative model that es-
timates continuous multimodal biomarker progressions for multiple diseases si-
multaneously – including rare neurodegenerative diseases – and which inherently
performs transfer learning between the modelled phenotypes. This is achieved
by exploiting biomarker relationships that are shared across diseases, whilst ac-
counting for differences in the spatial distribution of brain pathology. DKT is
interpretable, which allows us to understand underlying disease mechanisms, and
can also predict the future evolution of subjects at risk of diseases. We apply
DKT on Alzheimer’s variants and demonstrate its ability to predict non-MRI tra-
jectories for patients with Posterior Cortical Atrophy, in lack of such data. This
is done by fitting DKT to two datasets simultaneously: (1) the TADPOLE Chal-
lenge [6] dataset containing subjects from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) with MRI, FDG-PET, DTI, AV45 and AV1451 scans and (2)
MRI scans from patients with Posterior Cortical Atrophy from the Dementia
Research Centre (DRC), UK. We finally validate DKT on three datasets: 1)
simulated data with known ground truth, 2) TADPOLE sub-populations with
different progressions and 3) 20 DTI scans from controls and PCA patients from
our clinical center.
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Fig. 1: Diagram of the proposed DKT framework. We assume that each disease
can be modelled as the evolution of abstract dysfunction scores (Y-axis, top row),
each one related to different brain regions. Each region-specific dysfunction score
then further models (X-axis, bottom row) the progression of several multimodal
biomarkers within that same region. For instance, the temporal dysfunction,
modelled as a biomarker in the disease specific model (top row), is the X-axis
in the disease agnostic model (temporal unit, bottom row), which aggregates
together abnormality from amyloid, tau and MR imaging within the temporal
lobe. The biomarker relationships within the bottom units are assumed to be
disease agnostic and shared across all diseases modelled. Knowledge transfer
between the two diseases can then be achieved via the disease-agnostic units.
Mathematical notation from section 2 is shown in red to ease understanding.
2 Method
Fig. 1 shows the diagram of the DKT framework. We assume that the pro-
gression of each disease can be modelled as a unique evolution of dysfunction
trajectories representing region-specific multimodal pathology, further modelled
as the progression of several biomarkers within that same region, but acquired
using different modalities (Fig. 1 bottom). Each group of biomarkers in the bot-
tom row will be called a disease-agnostic unit or simply agnostic unit, because
biomarker dynamics here are assumed to be shared across all diseases modelled.
The assumption that the dynamics of some biomarkers are disease-agnostic
(i.e. shared across diseases), is key to DKT. We can make this assumption for
two reasons. First, pathology in many related neurodegenerative diseases (e.g.
Alzheimer’s variants) is hypothesised to share the same underlying mechanisms
(e.g. amyloid and tau accumulation), and within one region, such mechanisms
lead to similar pathology dynamics across all the disease variants modelled [7],
with the key difference that distinct brain regions are affected at different times
and with different pathology rates and extent, likely caused by selective vulner-
ability of networks within these regions [8]. Secondly, even if the diseases share
different upstream mechanisms (e.g. amyloid vs tau accumulation), downstream
biomarkers measuring hypometabolism, white matter degradation and atrophy
are likely to follow the same pathological cascade and will have similar dynamics.
We now model the biomarker dynamics that are specific to each disease, by
mapping the subjects’ disease stages to dysfunction scores. We assume that each
subject i at each visit j has an underlying disease stage sij = βi + mij , where
mij represents the months since baseline visit for subject i at visit j and βi
represents the time shift of subject i. We then assume that each subject i at
visit j has a dysfunction score γlij corresponding to multimodal pathology in
brain region l, which is a function of its disease stage:
γlij = f(βi +mij ;λ
l
di) (1)
where f is a smooth monotonic function mapping each disease stage to a dys-
function score, having parameters λldi corresponding to agnostic unit l ∈ Λ,
where Λ is the set of all agnostic units. Moreover, di ∈ D represents the index
of the disease corresponding to subject i, where D is the set of all diseases mod-
elled. For example, MCI and tAD subjects from ADNI as well as tAD subjects
from the DRC cohort can all be assigned di = 1, while PCA subjects can be
assigned di = 2. We implement f as a parametric sigmoidal curve similar to [2],
to enable a robust optimisation and because this accounts for floor and ceiling
effects present in AD biomarkers – the monotonicity of this sigmoidal family is
also very appropriate for many neurodegenerative diseases due to irreversability.
We further model the biomarker dynamics that are disease-agnostic, by con-
structing the mapping from the dysfunction scores γlij to the biomarker measure-
ments. We assume a set of given biomarker measurements Y = [yijk|(i, j, k) ∈ Ω]
for subject i at visit j in biomarker k, where Ω is the set of available biomarker
measurements. We further denote by θk the trajectory parameters for biomarker
k ∈ K within its agnostic unit ψ(k), where ψ: {1, ..., K} → Λ maps each
biomarker k to a unique agnostic unit l ∈ Λ. These definitions allow us to for-
mulate the likelihood for a single measurement yijk as follows:
p(yijk|θk, λψ(k)di , βi, k) = N(yijk|g(γ
ψ(k)
ij ; θk), k) (2)
where g( . ; θk) represents the trajectory of biomarker k within agnostic unit
ψ(k), with parameters θk, and is again implemented using a sigmoidal function
for reasons outlined above. Parameters λ
ψ(k)
di
are used to define γ
ψ(k)
ij based on
Eq. 1, where agnostic unit l is now referred to as ψ(k), to clarify this is the
unit where biomarker k has been allocated. Variable k denotes the variance of
measurements for biomarker k.
We extend the above model to multiple subjects, visits and biomarkers to
get the full model likelihood:
p(y|θ, λ, β, ) =
∏
(i,j,k)∈Ω
p(yijk|θk, λψ(k)di , βi) (3)
where y = [yijk|∀(i, j, k) ∈ Ω] is the vector of all biomarker measurements,
while θ = [θ1, ..., θK ] represents the stacked parameters for the trajectories of
biomarkers in agnostic units, λ = [λld|l ∈ Λ, d ∈ D] are the parameters of
the dysfunction trajectories within the disease models, β = [β1, ..., βN ] are the
subject-specific time shifts and  = [k|k ∈ K] estimates measurement noise.
We estimate the model parameters [θ,λ,β, ] using loopy belief propagation
– see algorithm in supplementary material. One key advantage of DKT is that
the subject’s time shift βi can be estimated using only a subset (e.g. MRI) of the
subject’s data – the model can then infer the missing modalities (e.g. non-MRI)
using Eq. 3.
2.1 Generating Synthetic Data
We first test DKT on synthetic data, to assess its performance against known
ground truth. More precisely, we generate data that follows the DKT model
exactly, and test DKT’s ability to recover biomarker trajectories and subject
time-shifts. We generate synthetic data from two diseases (50 subjects with ”syn-
thetic PCA” and 100 subjects with ”synthetic AD”) using the parameters from
the bottom-left table in Fig. 2, emulating the TADPOLE and DRC cohorts
– see supplementary material for full details. The six biomarkers (k1-k6) have
been a-priori allocated to two agnostic units l0 and l1. To simulate the lack
of multimodal data in the synthetic PCA subjects, we discarded the data from
biomarkers k0, k1, k4 and k5 for all these subjects.
2.2 Data Acquisition and Preprocessing
We trained DKT on ADNI data from the TADPOLE challenge [6], since it
contained a large number of multimodal biomarkers already pre-processed and
aggregated into one table. From the TADPOLE dataset we selected a subset of
230 subjects which had an MRI scan and at least one FDG PET, AV45, AV1451
or DTI scan. In order to model another disease, we further included MRI scans
from 76 PCA subjects from the DRC cohort, along with scans from 67 tAD and
87 age-matched controls.
For both datasets, we computed multimodal biomarker measurements corre-
sponding to each brain lobe: MRI volumes using the Freesurfer software, FDG-,
AV45- and AV1451-PET standardised uptake value ratios (SUVR) extracted
with the standard ADNI pipeline, and DTI fractional anisotropy (FA) measures
from adjacent white-matter regions. For every lobe, we regressed out the follow-
ing covariates: age, gender, total intracranial volume (TIV) and dataset (ADNI
vs DRC). Finally, biomarkers were normalized to the [0,1] range.
3 Results on Synthetic and Patient Datasets
Results on synthetic data in the presence of ground truth (Fig. 2) suggest that
DKT can robustly estimate the trajectory parameters (MAE < 0.058) as well
as the subject-specific time-shifts (R2 > 0.98). While some errors in trajectory
estimation can be noticed, these are due to the informed priors on the model
parameters in order to ensure identifiability and convergence of parameters.
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λ11 = (1, 0.2,−4, 0)
Fig. 2: Comparison between true and DKT-estimated subject time-shifts and
biomarker trajectories. (top-left/top-middle) Scatter plots of the true shifts (y-
axis) against estimated shifts (x-axis), for the ’synthetic AD’ and ’synthetic PCA’
diseases. We then show the DKT-estimated and true trajectories of the agnostic
units within the ’synthetic AD’ disease (top-right, ”Dis0”) and the ’synthetic
PCA’ disease (bottom-left, ”Dis1”). Finally, we also show the biomarker trajec-
tories within unit 0 (bottom-center) and unit 1 (bottom-right). Parameters used
for generating the trajectory shapes are shown in the table on the right.
We then apply DKT to real patient data, with the aim of transferring multi-
modal biomarker trajectories from tAD to PCA. The inferred PCA trajectories,
shown in Fig. 3, recapitulate known patterns in PCA [9], where posterior regions
such as occipital and parietal lobes are predominantly affected in later stages.
As opposed to typical AD, we find that the hippocampus is affected later on,
further suggesting the model did not transfer too much tAD specific information.
Here, we demonstrate the possibility of inferring plausible non-MRI biomarkers
in a rare neurodegenerative disease, in lack of such data for these subjects. As
far as we are aware, this is the first time a continuous signature of non-MRI
biomarkers is estimated for PCA, due to its rarity and lack of data.
3.1 Validation on DTI Data in tAD and PCA
We further validated DKT by predicting unseen DTI data from two patient
datasets: 1) TADPOLE subjects with a different progression from the training
Fig. 3: Estimated trajectories for the PCA cohort. The only data that were avail-
able were the MRI volumetric data. The dynamics of the other biomarkers has
been inferred by the model using data from typical AD, and taking into account
the different spatial distribution of pathology in PCA vs tAD.
subjects, and 2) a separate test set of 20 DTI scans from controls and PCA
patients from the DRC – full demographics are given in the supplementary ma-
terial. To split TADPOLE into subgroups with different progression, we used the
SuStaIn model by [3], which resulted into three subgroups: hippocampal, corti-
cal and subcortical, with prominent early atrophy in the hippocampus, cortical
and subcortical regions respectively. To evaluate prediction accuracy, we com-
puted the rank correlation between the DKT-predicted biomarker values and
the measured values in the test data. We compute the rank correlation instead
of mean squared error as it is not susceptible to systemic biases of the models
when predicting ”unseen data” in a certain disease.
Validation results are shown in Table 1, for hippocampal to cortical TAD-
POLE subgroups (other pairs of subgroups not shown due to lack of space) as
well as PCA subjects. When predicting missing DTI markers of the TADPOLE
cortical subgroup as well as PCA subjects from the DRC cohort (Table 1), the
DKT correlations are generally high for the cingulate, hippocampus and parietal,
and lower for the frontal lobe. DKT also shows favourable performance compared
to four other models: the latent-stage model from [2], a multivariate Gaussian
Process model with RBF kernel that predicts a DTI ROI marker from multiple
MRI markers, as well as cubic spline and linear models that predict a regional
DTI biomarker directly from its corresponding MRI marker. In particular for
predicting DTI FA in the parietal and temporal lobes, DKT has significantly
better predictions that almost all methods tested.
4 Discussion
In this work we made initial steps at the challenging problem of transfer learn-
ing between different neurodegenerative diseases. Our proposed DKT method
Model Cingulate Frontal Hippocam. Occipital Parietal Temporal
TADPOLE: Hippocampal subgroup to Cortical subgroup
DKT (ours) 0.56 ± 0.23 0.35 ± 0.17 0.58 ± 0.14 -0.10 ± 0.29 0.71 ± 0.11 0.34 ± 0.26
Latent stage 0.44 ± 0.25 0.34 ± 0.21 0.34 ± 0.24* -0.07 ± 0.22 0.64 ± 0.16 0.08 ± 0.24*
Multivariate 0.60 ± 0.18 0.11 ± 0.22* 0.12 ± 0.29* -0.22 ± 0.22 -0.44 ± 0.14* -0.32 ± 0.29*
Spline -0.24 ± 0.25* -0.06 ± 0.27* 0.58 ± 0.17 -0.16 ± 0.27 0.23 ± 0.25* 0.10 ± 0.25*
Linear -0.24 ± 0.25* 0.20 ± 0.25* 0.58 ± 0.17 -0.16 ± 0.27 0.23 ± 0.25* 0.13 ± 0.23*
typical Alzheimer’s to Posterior Cortical Atrophy
DKT (ours) 0.77 ± 0.11 0.39 ± 0.26 0.75 ± 0.09 0.60 ± 0.14 0.55 ± 0.24 0.35 ± 0.22
Latent stage 0.80 ± 0.09 0.53 ± 0.17 0.80 ± 0.12 0.56 ± 0.18 0.50 ± 0.21 0.32 ± 0.24
Multivariate 0.73 ± 0.09 0.45 ± 0.22 0.71 ± 0.08 -0.28 ± 0.21* 0.53 ± 0.22 0.25 ± 0.23*
Spline 0.52 ± 0.20* -0.03 ± 0.35* 0.66 ± 0.11* 0.09 ± 0.25* 0.53 ± 0.20 0.30 ± 0.21*
Linear 0.52 ± 0.20* 0.34 ± 0.27 0.66 ± 0.11* 0.64 ± 0.17 0.54 ± 0.22 0.30 ± 0.21*
Table 1: Performance evaluation of DKT and four other statistical models of de-
creasing complexity. We show the rank correlation between predicted biomarkers
and measured biomarkers in (top) TADPOLE subgroups and (bottom) PCA. (*)
Statistically significant difference in the performance of DKT vs the other mod-
els, based on a two-tailed t-test, Bonferroni corrected.
enabled the estimation of quantitative non-MRI trajectories in a rare disease
(PCA) where very limited data was available. To our knowledge, this is the first
time a multimodal continuous signature is derived for PCA, as the only other
longitudinal study of PCA only computed atrophy measures from MRI scans
[10]. Our work has however several limitations, which can be addressed in future
research: 1) to account for population heterogeneity, DKT can be easily extended
to include subject-specific effects; 2) improved schemes for biomarker allocation
to agnostic units can take connectivity into account, or derive it from the data
automatically; 3) DKT can be further validated on more complex synthetic ex-
periments with a range of datasets generated with different parameters.
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6 Supplementary material
6.1 Parameter Estimation
We estimate the model parameters using a two-stage approach. In the first stage,
we perform belief propagation within each agnostic unit and then within each dis-
ease model. In the second stage we jointly optimise across all agnostic units and
disease models using loopy belief propagation. An overview of the algorithm is
given in Figure 4. Given the initial parameters estimated from the first stage (line
1), the algorithm continuously updates the biomarker trajectories within the ag-
nostic units (lines 4-5), dysfunction trajectories (line 8) and subject-specific time
shifts (line 10) until convergence. The cost function for all parameters is nearly
identical, the main difference being the measurements (i, j, k) over subjects i, vis-
its j and biomarkers k that are selected for computing the measurement error.
For estimating the trajectory of biomarker k within agnostic unit ψ(k), measure-
ments are taken from Ωk representing all measurements of biomarker k from all
subjects and visits. For estimating the dysfunction trajectories, Ωd,l represents
the measurement indices from all subjects with disease d (i.e. di = d) and all
biomarkers k that belong to agnostic unit l (i.e. ψ(k) = l). Finally, Ωi (line 10)
represents all measurements from subject i, for all biomarkers and visits.
1 Initialise θ(0), λ(0), β(0)
2 while θ, λ, β not converged do
; // Estimate biomarker trajectories (disease agnostic)
3 for k = 1 to K do
4 θ
(u)
k = argminθk
∑
(i,j)∈Ωk
[
yijk − g
(
f(β
(u−1)
i +mij ;λ
ψ(k),(u−1)
di
); θk
)]2 − log p(θk)
5 
(u)
k =
1
|Ωk|
∑
(i,j)∈Ωk
[
yijk − g
(
f(β
(u−1)
i +mij ;λ
ψ(k),(u−1)
di
); θ
(u)
k
)]2
; // Estimate dysfunction trajectories (disease specific)
6 for d = 1 ∈ D do
7 for l = 1 ∈ Λ do
8 λ
l,(u)
d = argminλl
d
∑
(i,j,k)∈Ωd,l
[
yijk − g
(
f(β
(u−1)
i +mij ;λ
l
d); θ
(u)
k
)]2 − log p(λld)
; // Estimate subject-specific time shifts
9 for i = 1 ∈ [1, . . . , S] do
10 β
(u)
i = argminβi
∑
(j,k)∈Ωi
[
yijk − g
(
f(βi +mij ;λ
ψ(k),(u)
di
); θ
(u)
k
)]2 − log p(βi)
Fig. 4: The algorithm used to estimate the DKT parameters, based on loopy
belief-propagation.
6.2 Generation of synthetic dataset
We tested DKT on synthetic data, to assess its performance against known
ground truth. More precisely, we generated data that follows the DKT model
exactly, and tested DKT’s ability to recover biomarker trajectories and subject
time-shifts.
We generated the synthetic data as follows, using parameters from Table 2:
– We simulate two synthetic diseases, ”synthetic PCA” and ”synthetic AD”
– We define 6 biomarkers that we allocate to agnostic units l0 and l1 (Table 2
top)
– Within each agnostic unit, we define the parameters {θ0, ..., θ5} correspond-
ing to biomarker trajectories within the agnostic unit.
– For each disease, we define the parameters λ corresponding to trajectories
of dysfunction scores.
– We then sample data from 100 synthetic AD subjects and 50 PCA subjects
with βi as given in Table 2 bottom using the model likelihood (Eq. 2 from
main paper). For each subject, we generate data for 4 visits, each 1 year
apart.
Trajectory parameters
Biomarker allocation l0 : {k0, k2, k4}, l1 : {k1, k3, k5}
Agnostic unit l0 θ0 = (1, 5, 0.2, 0), θ2 = (1, 5, 0.55, 0), θ4 = (1, 5, 0.9, 0)
Agnostic unit l1 θ1 = (1, 10, 0.2, 0), θ3 = (1, 10, 0.55, 0), θ5 = (1, 10, 0.9, 0)
”Synthetic AD” λ00 = (1, 0.3,−4, 0) and λ10 = (1, 0.2, 6, 0)
”Synthetic PCA” λ01 = (1, 0.3, 6, 0) and λ
1
1 = (1, 0.2,−4, 0)
Subject parameters
Number of subjects 100 (synthetic AD) and 50 (synthetic PCA)
Time-shifts βi βi ∼ U(−13, 10) years
Diagnosis p(control) ∝ Exp(−4.5), p(patient) ∝ Exp(4.5)
Data generation 4 visits/subject, 1 year apart, k = 0.05
Table 2: Parameters used for synthetic data generation, emulating the TAD-
POLE and DRC datasets.
6.3 Demographics of test sets
The cohort from the Dementia Research Centre UK used for validation consisted
of 10 subjects diagnosed with Posterior Cortical Atrophy, with a mean age of
59.4, 40% females, as well as 10 age-matched controls with a mean age of 59.3,
50% females.
For the validation on TADPOLE subgroups, we used applied the SuStaIn
model on TADPOLE to split the population into three subgroups with differ-
ent progression: hippocampal, cortical and subcortical subypes with prominent
atrophy in the hippocampus, cortical and subcortical areas respectively. The
resulting subgroups had the following demographics:
Cohort Nr. subjects Nr. visits Age (baseline) Gender (%F)
Controls (Hippocampal) 31 2.3 ± 1.8 74.4 ± 6.9 38%
AD (Hippocampal) 21 1.5 ± 0.8 74.5 ± 5.5 42%
Controls (cortical) 21 2.3 ± 1.3 70.9 ± 5.4 42%
AD (cortical) 35 1.7 ± 0.9 72.8 ± 7.4 28%
Controls (subcortical) 28 3.0 ± 1.5 73.7 ± 6.5 42%
AD (subcortical) 27 1.6 ± 0.9 73.7 ± 7.5 33%
Table 3: Demographics of the subjects in the three TADPOLE subgroups.
